Advances in Nanostructured Lipid Carriers for Colorectal Cancer Treatment: A Comprehensive Review.

Riya Patel, Shailvi Shah, Sheetal Acharya, Gayatri Patel, Shreeraj Shah, Bhupendra G Prajapati
{"title":"Advances in Nanostructured Lipid Carriers for Colorectal Cancer Treatment: A Comprehensive Review.","authors":"Riya Patel, Shailvi Shah, Sheetal Acharya, Gayatri Patel, Shreeraj Shah, Bhupendra G Prajapati","doi":"10.2174/0115672018340391250321041056","DOIUrl":null,"url":null,"abstract":"<p><p>As colorectal cancer is the third most common cancer globally, this study aimed to improve colorectal cancer treatment using nanostructured lipid carriers (NLCs) for drug delivery by overcoming the current drawbacks, improving therapeutic effectiveness, achieving site-specific delivery, and implementing controlled drug administration to mitigate systemic side effects. Based on the literature, it has been observed that the optimal drug size and zeta potential range depend on the drug formulation's targets and features. These ranges are determined through optimization and characterization. The particle size ranges from 10 to 200 manometers, and the zeta potential values range from -30 mV to +30 mV. Optimal formulations should have uniform spherical morphology and compatibility with biological entities. This paper provides an in-depth analysis of nanocarrier research and findings. This article offers a thorough synopsis of the latest research and findings on nanocarriers, offering a valuable understanding of their development.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115672018340391250321041056","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

As colorectal cancer is the third most common cancer globally, this study aimed to improve colorectal cancer treatment using nanostructured lipid carriers (NLCs) for drug delivery by overcoming the current drawbacks, improving therapeutic effectiveness, achieving site-specific delivery, and implementing controlled drug administration to mitigate systemic side effects. Based on the literature, it has been observed that the optimal drug size and zeta potential range depend on the drug formulation's targets and features. These ranges are determined through optimization and characterization. The particle size ranges from 10 to 200 manometers, and the zeta potential values range from -30 mV to +30 mV. Optimal formulations should have uniform spherical morphology and compatibility with biological entities. This paper provides an in-depth analysis of nanocarrier research and findings. This article offers a thorough synopsis of the latest research and findings on nanocarriers, offering a valuable understanding of their development.

纳米结构脂质载体在结直肠癌治疗中的研究进展
由于结直肠癌是全球第三大常见癌症,本研究旨在改善使用纳米结构脂质载体(nlc)进行药物递送的结直肠癌治疗,克服目前的缺点,提高治疗效果,实现部位特异性递送,并实施控制给药以减轻全身副作用。根据文献观察,最佳药物大小和zeta电位范围取决于药物制剂的靶点和特征。这些范围是通过优化和表征确定的。粒径范围为10 ~ 200压力计,zeta电位值范围为-30 mV ~ +30 mV。最佳配方应具有均匀的球形形态和与生物实体的相容性。本文对纳米载体的研究成果进行了深入的分析。本文综述了纳米载体的最新研究成果,为纳米载体的发展提供了有价值的认识。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信